US 11,752,140 B2
Compositions comprising substituted benzofuroquinolizine and psychoactive drug
Outi Vainio, Turku (FI); Marja Raekallio, Helsinki (FI); Juhana Honkavaara, Helsinki (FI); Ira Kallio-Kujala, Vantaa (FI); Heta Turunen, Hämeenlinna (FI); Rachel Bennett, Winchester (GB); and Magdy Adam, Vantaa (FI)
Assigned to VETCARE OY, Salo (FI)
Appl. No. 16/98,037
Filed by VETCARE OY, Salo (FI)
PCT Filed May 8, 2017, PCT No. PCT/FI2017/050356
§ 371(c)(1), (2) Date Oct. 31, 2018,
PCT Pub. No. WO2017/194835, PCT Pub. Date Nov. 16, 2017.
Claims priority of application No. 20165395 (FI), filed on May 9, 2016.
Prior Publication US 2019/0125733 A1, May 2, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4375 (2006.01); A61K 31/4174 (2006.01); A61K 31/485 (2006.01); A61K 31/5517 (2006.01); A61K 9/00 (2006.01); A61K 31/135 (2006.01); A61K 45/06 (2006.01); A61P 25/20 (2006.01); A61P 23/00 (2006.01); A61K 31/4164 (2006.01)
CPC A61K 31/4375 (2013.01) [A61K 9/0019 (2013.01); A61K 31/135 (2013.01); A61K 31/4164 (2013.01); A61K 31/4174 (2013.01); A61K 31/485 (2013.01); A61K 31/5517 (2013.01); A61K 45/06 (2013.01); A61P 23/00 (2018.01); A61P 25/20 (2018.01)] 32 Claims
 
1. A syringe comprising a composition for use in sedation and/or anesthesia, wherein the composition comprises:
10-3000 μg/kg of MK-467;
at least one a psychoactive drug selected from the group consisting of midazolam, zolazepam, diazepam, ketamine, tiletamine, dextromethorphan, and phencyclidine,
at least one opioid selected from the group consisting of fentanyl, morphine, oxymorphine, buprenorphine, butorphanol tartrate, methadone, levomethadone, alfentanil, sufentanil, remifentanil, nalbuphine, pentazocine, oxymorphone, and hydromorphone, and
at least one excipient or carrier.